Evidence map›Paper›PMID 33689071›Full record

ArticleDoklady. Biochemistry and biophysics2021

GSK3 Kinase Inhibitor, CHIR, Suppress Transcription of Tissue Specific POU2F1 Isoform in Burkitt Namalwa Lymphoma Cells.

E V Pankratova, T N Portseva, A A Makarova, Yu V Ilyin, A G Stepchenko, S G Georgieva

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

E V PankratovaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia. panliz@mail.ru.
T N PortsevaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
A A MakarovaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
Yu V IlyinEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
A G StepchenkoEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
S G GeorgievaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
Engelhardt Institute of Molecular Biology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

POU2F1 (Oct-1) is a transcription factor, the overexpression of which is found in many human malignant tumors; a significant increase in its level in cells determines the malignant potential of the tumor. POU2F1 is represented in cells by several isoforms that are transcribed from alternative promoters. In Burkitt's B-cell lymphoma Namalwa, the concentration of tissue-specific isoform Oct-1L is several times higher than in normal B cells. We tested the potential to inhibit the transcription of individual Oct-1 isoforms using the GSK3 kinase inhibitor CHIR, an aminopyrimidine derivative. We have shown that CHIR specifically affects the expression of the tissue-specific isoform Oct-1L, significantly reducing the level of mRNA and Oct-1L protein. However, CHIR does not change the amount of mRNA and protein of the ubiquitous isoform Oct-1A in Namalwa tumor cells. The results obtained show that it is possible to develop a system for selective inhibition of Oct-1 transcription factor isoforms in human cells to suppress drug resistance of tumor cells with a high POU2F1 content.

Indexed as

Antineoplastic AgentsBurkitt LymphomaCell Line, TumorGlycogen Synthase Kinase 3HumansOctamer Transcription Factor-1Organ SpecificityPromoter Regions, GeneticProtein IsoformsProtein Kinase InhibitorsPyrimidinesTranscription, Genetic2-aminopyrimidineAntineoplastic AgentsGlycogen Synthase Kinase 3Octamer Transcription Factor-1POU2F1 protein, humanProtein IsoformsProtein Kinase InhibitorsPyrimidinesalternative promotersGSK3 kinasetranscription factor POU2F1(Oct-1)

Identifiers

PMID33689071
PMCPMC7946658
OpenAlexW3134319644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.